Serum Myostatin Levels in Chronic Heart Failure

Zamora, Elisabet; Simó, Rafael; Lupón, Josep; Galán, Amparo; Urrutia, Agustín; González, Beatríz; Mas, D.; Valle, Vicente

doi:10.1016/s1885-5857(10)70194-8

Cited by 14 publications

(15 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have carefully read the interesting article of George et al 1. and found some similarities, but also some differences, compared with our results 2,3. We assessed myostatin (MYOS) and MYOS pro‐peptide precursor (pro‐MYOS) serum levels by commercial ELISA in 70 heart failure (HF) patients [30 NYHA class I–II and 40 class III–IV; 66% of ischaemic aetiology, 10% with dilated cardiomyopathy; left ventricular ejection fraction (LVEF) 31.9 ± 12.3%] and analysed the relationship between these peptides and clinical parameters and prognosis 2,3.…”

supporting

confidence: 70%

Myostatin serum levels in heart failure

Zamora

Lupón

Simó

et al. 2010

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

supporting

confidence: 70%

Myostatin serum levels in heart failure

Zamora

Lupón

Simó

et al. 2010

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

“…Although Gruson et al had demonstrated that myostatin may be significantly increased in HF patients and that myostatin may correlate with biomarkers related to HF severity [25]. Zamora et al proposed that there was no relationship between the myostatin or myostatin propeptide level and any parameter of disease severity or prognosis in patients with chronic heart failure [26]. The insignificant change of myostatin in our heart failure patient may be attributed to the confounding effect of follistatin of which may antagonize myostatin during muscle mass regulation [27].…”

Section: Discussionmentioning

confidence: 99%

Relationship between Bone Mineral Density and Serum Osteoprotegerin in Patients with Chronic Heart Failure

Yang

Wang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

PurposeHeart failure (HF) had been reported with increased risk of hip fractures. However, the relationship between circulating biomarkers and bone mineral density (BMD) in chronic HF remained unclear.MethodsThis is a cross-sectional study which recruited stable chronic HF from registry of the Heart Failure Center of National Taiwan University Hospital. Patients underwent dual-energy x-ray absorptiometry (DEXA) measurements at hip and lumbar spines and biochemical assessments including B-type natriuretic peptide (BNP-32), myostatin, follistatin and osteoprotegerin (OPG).ResultsA total of 115 stable chronic HF individuals with left ventricular ejection fraction (EF) <45% (74% of male, mean age at 59) were recruited with 24 patients in NYHA class I, 73 patients in NYHA class II and 18 patients in NYHA class III. Results of BMD showed that Z scores of hip in NYHA III group (−0.12±1.15) was significantly lower than who were NYHA II (0.58±1.04). Serum OPG was significantly higher in subjects of NYHA III (9.3±4.6 pmol/l) than NYHA II (7.4±2.8 pmol/l) or NYHA I (6.8±3.6 pmol/l) groups. There’s a significant negative association between log transformed serum OPG and trochanteric BMD (R = −0.299, P = 0.001), which remained significant after multivariate analysis.ConclusionsOur study demonstrated an inverse association between serum OPG and trochanteric BMD in patients with HF. OPG may be a predictor of BMD and an alternative to DEXA for identifying at risk HF patients for osteoporosis.

show abstract

“…In addition, inhibition of myostatin in the mdx model of DMD accelerates the onset of systolic dysfunction and LV chamber dilatation [5]. In humans, myostatin has been reported to be increased in the serum [7], heart [8], and skeletal muscle [9] of adult HF patients, although one study did report decreased serum myostatin in HF patients [16]. In addition, we have previously reported that myostatin activation is increased in adult HF of both ischemic and non-ischemic etiologies [6], and now we have determined that myostatin expression is increased in HF secondary to CHD.…”

Section: Discussionmentioning

confidence: 99%

Myostatin Is Elevated in Congenital Heart Disease and After Mechanical Unloading

et al. 2011

View full text Add to dashboard Cite

BackgroundMyostatin is a negative regulator of skeletal muscle mass whose activity is upregulated in adult heart failure (HF); however, its role in congenital heart disease (CHD) is unknown.MethodsWe studied myostatin and IGF-1 expression via Western blot in cardiac tissue at varying degrees of myocardial dysfunction and after biventricular support in CHD by collecting myocardial biopsies from four patient cohorts: A) adult subjects with no known cardiopulmonary disease (left ventricle, LV), (Adult Normal), (n = 5); B) pediatric subjects undergoing congenital cardiac surgery with normal RV size and function (right ventricular outflow tract, RVOT), (n = 3); C) pediatric subjects with worsening but hemodynamically stable LV failure [LV and right ventricle (LV, RV,)] with biopsy collected at the time of orthotopic heart transplant (OHT), (n = 7); and D) pediatric subjects with decompensated bi-ventricular failure on BiVAD support with biopsy collected at OHT (LV, RV, BiVAD), (n = 3).ResultsThe duration of HF was longest in OHT patients compared to BIVAD. The duration of BiVAD support was 4.3±1.9 days. Myostatin expression was significantly increased in LV-OHT compared to RV-OHT and RVOT, and was increased more than double in decompensated biventricular HF (BiVAD) compared to both OHT and RVOT. An increased myostatin/IGF-1 ratio was associated with ventricular dysfunction.ConclusionsMyostatin expression in increased in CHD, and the myostatin/IGF-1 ratio increases as ventricular function deteriorates. Future investigation is necessary to determine if restoration of the physiologic myostatin/IGF-1 ratio has therapeutic potential in HF.

show abstract

Serum Myostatin Levels in Chronic Heart Failure

Cited by 14 publications

References 8 publications

Myostatin serum levels in heart failure

Myostatin serum levels in heart failure

Relationship between Bone Mineral Density and Serum Osteoprotegerin in Patients with Chronic Heart Failure

Myostatin Is Elevated in Congenital Heart Disease and After Mechanical Unloading

Contact Info

Product

Resources

About